{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:54:14Z","timestamp":1794963254639,"version":"4.9.1"},"reference-count":133,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtha.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:30:31Z","timestamp":1750174231000},"page":"3711-3732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-5295","authenticated-orcid":false,"given":"X. Long","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Al-Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Geldziler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Germini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Keepanasseril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Masias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Tarawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.002_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.med.53.082901.103948","article-title":"Thrombotic thrombocytopenic purpura: the systemic clumping \u201cplague.\u201d","volume":"53","author":"Moake","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.06.002_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2005-01-0152","article-title":"Localization of ADAMTS13 to the stellate cells of human liver","volume":"106","author":"Uemura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/labinvest.3700275","article-title":"ADAMTS13 is expressed in hepatic stellate cells","volume":"85","author":"Zhou","year":"2005","journal-title":"Lab Investig"},{"key":"10.1016\/j.jtha.2025.06.002_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1538-7836.2008.02989.x","article-title":"Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells","volume":"6","author":"Cao","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib8","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/blood-2006-02-002139","article-title":"Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts","volume":"108","author":"Shang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1538-7836.2006.01959.x","article-title":"Human endothelial cells synthesize and release ADAMTS-13","volume":"4","author":"Turner","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib10","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.20051732","article-title":"Systemic antithrombotic effects of ADAMTS13","volume":"203","author":"Chauhan","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib12","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1084\/jem.20080130","article-title":"ADAMTS13: a new link between thrombosis and inflammation","volume":"205","author":"Chauhan","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib13","doi-asserted-by":"crossref","first-page":"11552","DOI":"10.1073\/pnas.192448999","article-title":"A new name in thrombosis, ADAMTS13","volume":"99","author":"Sadler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.06.002_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Ann Rev Pathol"},{"key":"10.1016\/j.jtha.2025.06.002_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1046\/j.1537-2995.1992.32893032096.x","article-title":"Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group","volume":"32","author":"Rock","year":"1992","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2025.06.002_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLOS One"},{"key":"10.1016\/j.jtha.2025.06.002_bib19","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib20","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib21","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0950-3536(98)80064-4","article-title":"Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Furlan","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib23","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib24","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jtha.2024.02.003","article-title":"Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura","volume":"22","author":"Zheng","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of Anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtha.2025.06.002_bib26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","article-title":"A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom","volume":"10","author":"Camilleri","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib28","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib29","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1073\/pnas.172277399","article-title":"Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity","volume":"99","author":"Kokame","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.06.002_bib30","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2002-12-3796","article-title":"ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity","volume":"101","author":"Savasan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1538-7933.2004.00623.x","article-title":"Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw\u2013Schulman syndrome)","volume":"2","author":"Veyradier","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1160\/TH05-12-0817","article-title":"A common origin of the 4143insA ADAMTS13 mutation","volume":"96","author":"Schneppenheim","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1160\/TH07-01-0059","article-title":"Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw\u2013Schulman syndrome)","volume":"98","author":"Hommais","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib34","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/pbc.24594","article-title":"Novel frameshift mutations in ADAMTS13 in two families with hereditary thrombotic thrombocytopenic purpura","volume":"60","author":"Alsultan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2025.06.002_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ejh.12197","article-title":"Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene","volume":"92","author":"Rank","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jth.12804","article-title":"The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice","volume":"13","author":"De Cock","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib37","first-page":"709","article-title":"Genetic and functional characterization of ADAMTS13 variants in a patient cohort with Upshaw-Schulman syndrome investigated in Germany","volume":"118","author":"Hassenpflug","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtha.2022.12.003","article-title":"In vitro characterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain","volume":"21","author":"De Waele","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2138306","article-title":"Inherited ADAMTS13 mutations associated with thrombotic thrombocytopenic purpura: a short review and update","volume":"34","author":"Markham-Lee","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2025.06.002_bib40","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib41","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib42","first-page":"7","article-title":"Chinese guideline on the diagnosis and management of thrombotic thrombocytopenic purpura (2022)","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jtha.2025.06.002_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","article-title":"Research on Rare and Intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib46","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/ndt\/gfac034","article-title":"European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis","volume":"37","author":"Eller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtha.2025.06.002_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103722","article-title":"Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: case series","volume":"62","author":"Albanell\u2013Fernandez","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2025.06.002_bib49","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00277-023-05211-8","article-title":"Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program","volume":"102","author":"de Oliveira Boechat","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2157807","article-title":"Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience","volume":"34","author":"Tse","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2025.06.002_bib51","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib52","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/trf.17111","article-title":"Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: a single-center with homogeneous treatment experience","volume":"62","author":"Jimenez","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2025.06.002_bib53","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib54","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/jth.15406","article-title":"The standard of care for immune thrombotic thrombocytopenic purpura today","volume":"19","author":"Zheng","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib55","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib56","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib57","first-page":"277","article-title":"Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States","volume":"31","author":"Sullivan","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jtha.2025.06.002_bib58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange","volume":"144","author":"Kuhne","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib59","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.06.002_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib61","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity","volume":"46","author":"Kato","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2025.06.002_bib62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ajh.21220","article-title":"Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method","volume":"83","author":"Knovich","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib63","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1055\/s-0038-1641151","article-title":"Evaluation of the fully automated HemosIL Acustar ADAMTS13 activity assay","volume":"118","author":"Favresse","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib64","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity","volume":"119","author":"Valsecchi","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/978-1-0716-3175-1_32","article-title":"Automated and rapid ADAMTS13 testing using chemiluminescence: utility for identification or exclusion of TTP and beyond","volume":"2663","author":"Favaloro","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtha.2025.06.002_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib68","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood-2002-05-1397","article-title":"Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)","volume":"100","author":"Plaimauer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib69","doi-asserted-by":"crossref","first-page":"30136","DOI":"10.1074\/jbc.M305331200","article-title":"Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13","volume":"278","author":"Zheng","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.06.002_bib70","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1161\/ATVBAHA.111.229609","article-title":"Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis","volume":"31","author":"Xiao","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.06.002_bib71","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib72","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in severe neonatal thrombotic thrombocytopenic purpura","volume":"387","author":"Stubbs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib73","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2023-188996","article-title":"Recombinant ADAMTS13 for the treatment of acute TTP events in patients with congenital thrombotic thrombocytopenic purpura: results from the phase 3 randomized, controlled, crossover study and the phase 3b continuation study","volume":"142","author":"Scully","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib74","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura","volume":"390","author":"Scully","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib75","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1182\/bloodadvances.2024013265","article-title":"Recombinant ADAMTS13: an effective rescue therapy for acute cTTP during pregnancy","volume":"8","author":"Dadoun","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib76","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ijgo.14918","article-title":"Long-term survival and renal outcomes of thrombotic microangiopathy in pregnancy: a retrospective cohort study","volume":"163","author":"Chen","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jtha.2025.06.002_bib77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12882-023-03200-7","article-title":"Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy for essential thrombocythemia: a case report","volume":"24","author":"Qin","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jtha.2025.06.002_bib78","article-title":"Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship","volume":"10","author":"Selvakumar","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.06.002_bib79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18127","article-title":"Mind and matter: the neurological complications of thrombotic thrombocytopenic purpura","volume":"197","author":"Shaw","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib81","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2141.2010.08091.x","article-title":"Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura","volume":"149","author":"Viswanathan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib82","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2022016044","article-title":"Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura","volume":"140","author":"Borogovac","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib83","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s11239-021-02629-7","article-title":"Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes","volume":"53","author":"Beltrami\u2013Moreira","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.002_bib84","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0040-1722610","article-title":"Cerebral infarction in immune thrombotic thrombocytopenic purpura is associated with old age, hypertension, smoking, and anti-ADAMTS13 Ig, but not with mortality","volume":"5","author":"Memon","year":"2021","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.06.002_bib85","series-title":"Clinical Practice Guidelines We Can Trust","article-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"key":"10.1016\/j.jtha.2025.06.002_bib86","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Schunemann","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2025.06.002_bib87","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.06.002_bib88","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood-2023-189416","article-title":"Clinical outcomes of congenital thrombotic thrombocytopenic purpura: a multinational chart review study","volume":"142","author":"Coppo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib89","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"Borogovac","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib90","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17474086.2023.2202850","article-title":"Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"16","author":"He","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib91","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/bloodadvances.2022009448","article-title":"Caplacizumab as frontline therapy in addition to standard treatment in iTTP","volume":"7","author":"Cid","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib92","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.thromres.2023.06.018","article-title":"Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"228","author":"Caocci","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.002_bib93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjh.18915","article-title":"Caplacizumab: a game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?","volume":"202","author":"Coppo","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib94","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00277-021-04685-8","article-title":"Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era","volume":"101","author":"Del Rio\u2013Garma","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000517813","article-title":"Effectiveness of caplacizumab nanobody in acquired thrombotic thrombocytopenic purpura refractory to conventional treatment","volume":"145","author":"Palanques\u2013Pastor","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib96","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-021-00992-5","article-title":"Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases","volume":"35","author":"Boudali","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.jtha.2025.06.002_bib97","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib98","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256024","article-title":"Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era","volume":"16","author":"Van de Louw","year":"2021","journal-title":"PLOS One"},{"key":"10.1016\/j.jtha.2025.06.002_bib100","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3390\/jcm10153418","article-title":"Post approval experience with caplacizumab for acquired thrombotic thrombocytopenic purpura at a single institution","volume":"10","author":"Logothetis","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (The Capla 1000+ project)","volume":"82","author":"Coppo","year":"2025","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.jtha.2025.06.002_bib102","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2025.06.002_bib103","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/bloodadvances.2019000939","article-title":"Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sui","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib104","doi-asserted-by":"crossref","first-page":"974","DOI":"10.5858\/arpa.2022-0050-RA","article-title":"ADAMTS13 Biomarkers in management of immune thrombotic thrombocytopenic purpura","volume":"147","author":"Sui","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib105","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/trf.12762","article-title":"Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura","volume":"55","author":"Wu","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2025.06.002_bib107","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood.2024027516","article-title":"Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data","volume":"145","author":"Sakai","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib108","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/17512433.2021.1944102","article-title":"Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?","volume":"14","author":"Elverdi","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.002_bib109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00277-022-05049-6","article-title":"Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura","volume":"102","author":"Meek","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib110","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib111","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib112","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2023011617","article-title":"Targeting neutrophil extracellular trap under flow in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"8","author":"Yada","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.002_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/089771502753754037","article-title":"Clinical trials in head injury","volume":"19","author":"Narayan","year":"2002","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.jtha.2025.06.002_bib114","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ajem.2020.11.019","article-title":"Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: a single center experience","volume":"46","author":"Li","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","article-title":"Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan","volume":"112","author":"Kubo","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib116","article-title":"Outcomes of immune thrombotic thrombocytopenic purpura (iTTP) with upfront cyclophosphamide vs rituximab","volume":"7","author":"Abou\u2013Ismail","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.06.002_bib117","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1744-9987.13502","article-title":"Clinical presentation and management of acquired thrombotic thrombocytopenic purpura: a case series of 55 patients","volume":"25","author":"Sun","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jtha.2025.06.002_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102185","article-title":"Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry","volume":"7","author":"Agosti","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib119","article-title":"Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data","volume":"10","author":"Gavriilaki","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.06.002_bib120","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"Knoebl","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12185-022-03495-6","article-title":"The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study","volume":"117","author":"Miyakawa","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib122","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/jth.15892","article-title":"Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study","volume":"20","author":"Scully","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib123","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"Volker","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12814","article-title":"Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease","volume":"6","author":"Tarasco","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib125","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib126","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib127","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.002_bib128","doi-asserted-by":"crossref","first-page":"177.e1","DOI":"10.1016\/j.ajog.2021.02.018","article-title":"Unfolding the pathophysiology of congenital thrombotic thrombocytopenic purpura in pregnancy: lessons from a cluster of familial cases","volume":"225","author":"Miodownik","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.06.002_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102687","article-title":"Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura","volume":"9","author":"Colliou","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","article-title":"Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw\u2013Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients","volume":"144","author":"Fujimura","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.002_bib131","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti\u2013Cohen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib132","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.002_bib133","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1055\/a-2253-9359","article-title":"ADAMTS13 or caplacizumab reduces the accumulation of neutrophil extracellular traps and thrombus in whole blood of COVID-19 patients under flow","volume":"124","author":"Yada","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.002_bib134","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/jth.15363","article-title":"Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab","volume":"19","author":"Schofield","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:55Z","timestamp":1793500015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1538783625003605"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.002","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}